Update: Epidemiologie und Prävention des Oropharynxkarzinoms

Andreas Dietz; Gunnar Wichmann; Susanne Wiegand; Tim Waterboer; Wilfried Budach; Jens Peter Klußmann

doi:10.1055/a-2133-2348

Laryngo-Rhino-Otologie, Table of Contents

Laryngorhinootologie 2024; 103(04): 296-313
DOI: 10.1055/a-2133-2348

Facharztwissen HNO

Update: Epidemiologie und Prävention des Oropharynxkarzinoms

Update: Epidemiology and Prevention of Oropharyngeal Cancer

Andreas Dietz

,

Gunnar Wichmann

,

Susanne Wiegand

,

Tim Waterboer

,

Wilfried Budach

,

Jens Peter Klußmann

Abstract

Beim Oropharynxkarzinom unterscheidet man inzwischen abhängig davon, ob eine HPV-16-Infektion ursächlich vorliegt oder nicht, in 2 verschiedene Entitäten. Neuere Daten zeigen ein diverses Bild der Bedeutung und Prävalenz des Surrogatparameters p16 (Diskordanz) für eine tatsächliche HPV-16-Assoziation. Im Rahmen der Präventionsmöglichkeiten kommt der Impfung eine hohe und dem HPV-Screening gesunder Menschen eine geringe Bedeutung zu.

Abstract

Due to the association with the causal HPV-16 infection, the oropharyngeal carcinoma spreads into two separate entities depending on HPV-16 positivity. More recent data show a diversified picture of the importance and prevalence of the surrogate parameter p16 (discordance) for a definitive HPV-16 association, which varies worldwide. In the context of prevention options, vaccination is of major and HPV screening of healthy people only of little importance.

Schlüsselwörter

Oropharynxkarzinom - p16 - HPV-16 - Prävention - Impfung - Vorsorge-Screening

Keywords

Oropharynx carcinoma - p16 - HPV-16 - prevention - vaccination - screening

Full Text

References

Literatur
1 Robert-Koch-Institut. Wissenschaftliche Begründung für die Empfehlung der HPV-Impfung für Jungen im Alter von 9–14 Jahren. Epidemiol Bull 2018; 26. www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2018/Ausgaben/26_18.pdf?__blob=publicationFile
2 Ang KK, Harris J, Wheeler R. et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363 (01) 24-35
3 Klussmann JP, Gültekin E, Weissenborn SJ. et al. Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol 2003; 162 (03) 747-753
4 Menezes FDS, Fernandes GA, Antunes JLF. et al. Global incidence trends in head and neck cancer for HPV-related and -unrelated subsites: A systematic review of population-based studies. Oral Oncol 2021; 115: 105177
5 Klussmann JP, Weissenborn SJ, Wieland U. et al. Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. Cancer 2001; 92 (11) 2875-2884
6 Castellsagué X, Alemany L, Quer M. et al. HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients. J Natl Cancer Inst 2016; 108: djv403
7 Reuschenbach M, Tinhofer I, Wittekindt C. et al. A systematic review of the HPV-attributable fraction of oropharyngeal squamous cell carcinomas in Germany. Cancer Med 2019; 8 (04) 1908-1918
8 Bayer O, Krüger M, Koutsimpelas D. et al. Changes in Incidence and Mortality Trends of Head and Neck Cancer in Rhineland-Palatinate, 2000–2009. Laryngorhinootologie 2015; 94 (07) 451-458
9 Tinhofer I, Jöhrens K, Keilholz U. et al. Contribution of human papilloma virus to the incidence of squamous cell carcinoma of the head and neck in a European population with high smoking prevalence. Eur J Cancer 2015; 51 (04) 514-521
10 Wittekindt C, Wagner S, Sharma SJ. et al. HPV – A different view on Head and Neck Cancer. Laryngorhinootologie 2018; 97 (Suppl. 01) S48-S113
11 Wittekindt C, Wagner S, Bushnak A. et al. Increasing Incidence rates of Oropharyngeal Squamous Cell Carcinoma in Germany and Significance of Disease Burden Attributed to Human Papillomavirus. Cancer Prev Res (Phila) 2019; 12 (06) 375-382
12 Liao CI, Francoeur AA, Kapp DS. et al. Trends in Human Papillomavirus-Associated Cancers, Demographic Characteristics, and Vaccinations in the US, 2001–2017. JAMA Netw Open 2022; 5 (03) e222530
13 Suchan M, Wuerdemann N, Sharma SJ. et al. HPV-related oropharyngeal squamous cell carcinoma-Incidence steadily rising. HNO 2021; 69 (07) 599-608
14 Dietz A, Wichmann G, Wiegand S. Update Treatment HPV-16-positive Oropharyngeal Carcinoma. Laryngorhinootologie 2021; 100 (10) 832-844
15 Internationale Arbeitsgruppe Kopf-Hals-Tumoren (IAG-KHT). Laufende Studien. www.krebsgesellschaft.de/deutsche-krebsgesellschaft-wtrl/deutsche-krebsgesellschaft/ueber-uns/organisation/sektion-b-arbeitsgemeinschaften/iag-kht.html
16 Maier H, Dietz A, Zielinski D. et al. Risk factors for squamous epithelial carcinoma of the mouth, the oropharynx, the hypopharynx and the larynx. Dtsch Med Wochenschr 1990; 115 (22) 843-850
17 Maier H, Dietz A, Gewelke U. et al. Tobacco- and alcohol-associated cancer risk of the upper respiratory and digestive tract. Laryngorhinootologie 1990; 69 (10) 505-511
18 Maier H, de Vries N, Weidauer H. Occupation and cancer of the oral cavity, pharynx and larynx. HNO 1990; 38 (08) 271-278
19 S3-Leitlinie Diagnostik und Therapie des Mundhöhlenkarzinoms. AWMF-Registernummer: 007/100OL, Version 3.0. 2021 www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Mundhoehlenkarzinom/Version_3/LL_Mundhoehlenkarzinom_Langversion_3.0.pdf
20 Bosetti C, Gallus S, Trichopoulou A. et al. Influence of the Mediterranean diet on the risk of cancers of the upper aerodigestive tract. Cancer Epidemiol Biomarkers Prev 2003; 12 (10) 1091-1094
21 Levi F, Pasche C, Lucchini F. et al. Refined and whole grain cereals and the risk of oral, oesophageal and laryngeal cancer. Eur J Clin Nutr 2000; 54 (06) 487-489
22 Uzcudun AE, Retolaza IR, Fernández PB. et al. Nutrition and pharyngeal cancer: results from a case-control study in Spain. Head Neck 2002; 24 (09) 830-840
23 Franceschi S, Favero A, Conti E. et al. Food groups, oils and butter, and cancer of the oral cavity and pharynx. Br J Cancer 1999; 80: 614-620
24 Riechelmann H. Occupational exposure and cancer of the oral cavity and pharynx. Laryngorhinootologie 2002; 81 (08) 573-579
25 Dietz A, Heller WD, Maier H. Epidemiologic aspects of cancers of the head-neck area. Offentl Gesundheitswes 1991; 53 (10) 674-680
26 Dietz A, Maier H. Occupational cancer. HNO 1997; 45 (07) 495-497
27 Maier H, Gewelke U, Dietz A. et al. Laryngeal cancer and occupation – results of the Heidelberg laryngeal cancer study. HNO 1992; 40 (02) 44-51
28 Weichert W, Ihrler S, Boxberg M. et al. Morphology of non cutaneous head and neck squamous cell carcinoma. Pathologe 2018; 39 (01) 3-10
29 Barnes L, Eveson JW, Reichart P, Sidransky D (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Head and Neck Tumours. IARC Press; 2005.
30 S3-Leitlinie Diagnostik, Therapie und Nachsorge des Larynxkarzinoms. Langversion 1.1, AWMF-Registernummer: 017/076OL. 2019 www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Larynxkarzinom/Version1.1/LL_Larynxkarzinom_Langversion_1.1.pdf
31 Wichmann G. Variation of HPV Subtypes with Focus on HPV-Infection and Cancer in the Head and Neck Region. Recent Results Cancer Res 2017; 206: 113-122
32 Wagner S, Würdemann N, Hübbers C. et al. HPV-associated head and neck cancer: mutational signature and genomic aberrations. HNO 2015; 63 (11) 758-767
33 Wichmann G, Rosolowski M, Krohn K. et al. The role of HPV RNA transcription, immune response-related gene expression and disruptive TP53 mutations in diagnostic and prognostic profiling of head and neck cancer. Int J Cancer 2015; 137 (12) 2846-2857
34 Lechner M, Liu J, Masterson L. et al. HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nat Rev Clin Oncol 2022; 19 (05) 306-327
35 Andl T, Kahn T, Pfuhl A. et al. Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Res 1998; 58 (01) 5-13
36 Klussmann JP, Weissenborn SJ, Wieland U. et al. Human papillomavirus-positive tonsillar carcinomas: a different tumor entity?. Med Microbiol Immunol 2003; 192 (03) 129-132
37 Shamseddine AA, Burman B, Lee NY. et al. Tumor Immunity and Immunotherapy for HPV-Related Cancers. Cancer Discov 2021; 11 (08) 1896-1912
38 Wagner S, Böckmann H, Gattenlöhner S. et al. The innate immune system in oropharyngeal squamous cell carcinoma: Immune modulation by HPV. HNO 2018; 66 (04) 301-307
39 Reimers N, Kasper HU, Weissenborn SJ. et al. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer 2007; 120 (08) 1731-1738
40 Golusiński W, Leemans CR, Dietz A. HPV infection in head and neck cancer. Heidelberg: Springer; 2016
41 Rischin D, Peters LJ, O’Sullivan B. et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 2010; 28 (18) 2989-2995
42 Freitag J, Wald T, Kuhnt T. et al. Extracapsular extension of neck nodes and absence of human papillomavirus 16-DNA are predictors of impaired survival in p16-positive oropharyngeal squamous cell carcinoma. Cancer 2020; 126 (09) 1856-1872
43 Mehanna H, Taberna M, von Buchwald C. et al. Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis. Lancet Oncol 2023; 24 (03) 239-251
44 Holmes BJ, Westra WH. The expanding role of cytopathology in the diagnosis of HPV-related squamous cell carcinoma of the head and neck. Diagn Cytopathol 2014; 42 (01) 85-93
45 LaPak KM, Burd CE. The molecular balancing act of p16(INK4a) in cancer and aging. Mol Cancer Res 2014; 12 (02) 167-183
46 Rayess H, Wang MB, Srivatsan ES. Cellular senescence and tumor suppressor gene p16. Int J Cancer 2012; 130 (08) 1715-1725
47 Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 2010; 10 (08) 550-560
48 Amin MB, Edge SB. American Joint Committee on Cancer AJCC cancer staging manual. Heidelberg: Springer; 2017. 8th ed.
49 Fakhry C, Lacchetti C, Rooper LM. et al. Human Papillomavirus Testing in Head and Neck Carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists Guideline. J Clin Oncol 2018; 36 (31) 3152-3161
50 Lewis JS, Beadle B, Bishop JA. et al. Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College of American Pathologists. Arch Pathol Lab Med 2018; 142 (05) 559-597
51 Shelton J, Purgina BM, Cipriani NA. et al. p16 immunohistochemistry in oropharyngeal squamous cell carcinoma: a comparison of antibody clones using patient outcomes and high-risk human papillomavirus RNA status. Mod Pathol 2017; 30 (09) 1194-1203
52 Ennis CM, Rohrbach MR, Schwalbe M. et al. A Comparison of E6H4 and G175–405 p16-specific Monoclonal Antibodies in Oropharyngeal Squamous Cell Carcinoma. Appl Immunohistochem Mol Morphol 2020; 28 (04) 290-295
53 Prigge ES, Arbyn M, von Knebel Doeberitz M. et al. Diagnostic accuracy of p16. Int J Cancer 2017; 140 (05) 1186-1198
54 Nauta IH, Rietbergen MM, van Bokhoven AAJD. et al. Evaluation of the eighth TNM classification on p16-positive oropharyngeal squamous cell carcinomas in the Netherlands and the importance of additional HPV DNA testing. Ann Oncol 2018; 29 (05) 1273-1279
55 Sathasivam HP, Santambrogio A, Andoniadou CL. et al. Prognostic utility of HPV specific testing in addition to p16 immunohistochemistry in oropharyngeal squamous cell carcinoma. Ann Oncol 2018; 29 (10) 2144-2145
56 Augustin JG, Lepine C, Morini A. et al. HPV Detection in Head and Neck Squamous Cell Carcinomas: What Is the Issue?. Front Oncol 2020; 10: 1751
57 O'Sullivan B, Huang SH, Su J. et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol 2016; 17 (04) 440-451
58 Huang SH, Xu W, Waldron J. et al. Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas. J Clin Oncol 2015; 33 (08) 836-845
59 Haughey BH, Sinha P, Kallogjeri D. et al. Pathology-based staging for HPV-positive squamous carcinoma of the oropharynx. Oral Oncol 2016; 62: 11-19
60 Huang SH, O'Sullivan B, Su J. et al. Prognostic importance of radiologic extranodal extension in HPV-positive oropharyngeal carcinoma and its potential role in refining TNM-8 cN-classification. Radiother Oncol 2020; 144: 13-22
61 Boscolo-Rizzo P, Dietz A. The AJCC/UICC eighth edition for staging head and neck cancers: Is it wise to de-escalate treatment regimens in p16-positive oropharyngeal cancer patients?. Int J Cancer 2017; 141 (07) 1490-1491
62 Becker C, Hofauer BG, Mansour N. et al. [The 8th edition of the TNM staging system – a curse or a blessing for oropharyngeal carcinoma?. ] HNO 2021; 69 (02) 89-94
63 Sharma SJ, Linke JJ, Kroll T. et al. Rigid Triple Endoscopy Improves Clinical Staging of Primary Head and Neck Cancer. Oncol Res Treat 2018; 41: 35-38
64 Craig SG, Anderson LA, Schache AG. et al. Recommendations for determining HPV status in patients with oropharyngeal cancers under TNM8 guidelines: a two-tier approach. Br J Cancer 2019; 120 (08) 827-833
65 Rasmussen JH, Grønhøj C, Håkansson K. et al. Risk profiling based on p16 and HPV DNA more accurately predicts location of disease relapse in patients with oropharyngeal squamous cell carcinoma. Ann Oncol 2019; 30 (04) 629-636
66 Wagner S, Prigge ES, Wuerdemann N. et al. Evaluation of p16. Br J Cancer 2020; 123 (07) 1114-1122
67 Holzinger D, Flechtenmacher C, Henfling N. et al. Identification of oropharyngeal squamous cell carcinomas with active HPV16 involvement by immunohistochemical analysis of the retinoblastoma protein pathway. Int J Cancer 2013; 133 (06) 1389-1399
68 Bussu F, Ragin C, Boscolo-Rizzo P. et al. HPV as a marker for molecular characterization in head and neck oncology: Looking for a standardization of clinical use and of detection method(s) in clinical practice. Head Neck 2019; 41 (04) 1104-1111
69 Chera BS, Kumar S, Beaty BT. et al. Rapid Clearance Profile of Plasma Circulating Tumor HPV Type 16 DNA during Chemoradiotherapy Correlates with Disease Control in HPV-Associated Oropharyngeal Cancer. Clin Cancer Res 2019; 25 (15) 4682-4690
70 Haring CT, Bhambhani C, Brummel C. et al. Human papilloma virus circulating tumor DNA assay predicts treatment response in recurrent/metastatic head and neck squamous cell carcinoma. Oncotarget 2021; 12 (13) 1214-1229
71 Tanaka H, Suzuki M, Takemoto N. et al. Performance of oral HPV DNA, oral HPV mRNA and circulating tumor HPV DNA in the detection of HPV-related oropharyngeal cancer and cancer of unknown primary. Int J Cancer 2022; 150 (01) 174-186
72 Cao Y, Haring CT, Brummel C. et al. Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma. Clin Cancer Res 2022; 28 (02) 350-359
73 Mattox AK, D'Souza G, Khan Z. et al. Comparison of next generation sequencing, droplet digital PCR, and quantitative real-time PCR for the earlier detection and quantification of HPV in HPV-positive oropharyngeal cancer. Oral Oncol 2022; 128: 105805
74 Haring CT, Dermody SM, Yalamanchi P. et al. The future of circulating tumor DNA as a biomarker in HPV related oropharyngeal squamous cell carcinoma. Oral Oncol 2022; 126: 105776
75 D'Souza G, Kreimer AR, Viscidi R. et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356 (19) 1944-1956
76 Wichmann G, Rudolph J, Henger S. et al. Is High-Risk Sexual Behavior a Risk Factor for Oropharyngeal Cancer?. Cancers (Basel) 2023; 15 (13)
77 Wiegand S, Wichmann G, Golusinski W. et al. Highlights from the Second International Symposium on HPV infection in head and neck cancer. Eur Arch Otorhinolaryngol 2018; 275 (06) 1365-1373
78 Doorbar J, Griffin H. Refining our understanding of cervical neoplasia and its cellular origins. Papillomavirus Res 2019; 7: 176-179
79 Hoffmann M, Quabius ES, Fabian A. et al. The interaction of smoking habit, SLPI and AnxA2 in HPV associated head and neck and other cancers. Cancer Treat Res Commun 2021; 26: 100299
80 Hoffmann M, Quabius ES. Relevance of Human Papillomaviruses in Head and Neck Cancer-What Remains in 2021 from a Clinician's Point of View?. Viruses 2021; 13 (06) 1173
81 Robert-Koch-Institut, Epidemiologisches Bulletin. Einfluss von Schulimpfprogrammen auf die HPV-Impfquote (20/2022). www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2022/Ausgaben/20_22.pdf?__blob=publicationFile
82 Robert-Koch-Institut, HVP-Impfung. Kurz & Knapp: Faktenblätter zum Impfen. 2019 www.rki.de/DE/Content/Infekt/Impfen/Materialien/Faktenblaetter/HPV.pdf?__blob=publicationFile
83 Gross GE, Werner RN, Avila Valle GL. et al. None. J Dtsch Dermatol Ges 2021; 19 (03) 479-494
84 Gross GE, Werner RN, Avila Valle GL. et al. German evidence and consensus-based (S3) guideline: Vaccination recommendations for the prevention of HPV-associated lesions. J Dtsch Dermatol Ges 2021; 19 (03) 479-494
85 Gross G, Becker N, Brockmeyer NH. et al. Vaccination against HPV-associated neoplasias. Laryngorhinootologie 2014; 93 (12) 848-856
86 Kreimer AR, Shiels MS, Fakhry C. et al. Screening for human papillomavirus-driven oropharyngeal cancer: Considerations for feasibility and strategies for research. Cancer 2018; 124 (09) 1859-1866
87 Franceschi S, Combes JD, Dalstein V. et al. Deep brush-based cytology in tonsils resected for benign diseases. Int J Cancer 2015; 137 (12) 2994-2999
88 Eggesmann TK, Baumeister P, Kumbrink J. et al. Oropharyngeal HPV Detection Techniques in HPV-associated Head and Neck Cancer Patients. Anticancer Res 2020; 40 (04) 2117-2123
89 Kreimer AR, Pierce Campbell CM, Lin HY. et al. Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. Lancet 2013; 382 (9895) 877-887
90 Martin-Gomez L, Fulp WJ, Schell MJ. et al. Oral gargle-tumor biopsy human papillomavirus (HPV) agreement and associated factors among oropharyngeal squamous cell carcinoma (OPSCC) cases. Oral Oncol 2019; 92: 85-91
91 Loermann G, Kolb M, Prascevic D. et al. High-Risk Human Papillomavirus (HR-HPV) DNA Detection in Mouthwashes for Diagnosis of HPV-Driven Oropharynx Cancer and Its Curative Therapy – A Feasibility Study. J Clin Med 2022; 11 (19) 5509
92 Hibbert J, Halec G, Baaken D. et al. Sensitivity and Specificity of Human Papillomavirus (HPV) 16 Early Antigen Serology for HPV-Driven Oropharyngeal Cancer: A Systematic Literature Review and Meta-Analysis. Cancers (Basel) 2021; 13 (12)
93 Kreimer AR, Johansson M, Yanik EL. et al. Kinetics of the Human Papillomavirus Type 16 E6 Antibody Response Prior to Oropharyngeal Cancer. J Natl Cancer Inst 2017; 109 (08)
94 Kreimer AR, Ferreiro-Iglesias A, Nygard M. et al. Timing of HPV16-E6 antibody seroconversion before OPSCC: findings from the HPVC3 consortium. Ann Oncol 2019; 30 (08) 1335-1343
95 Robbins HA, Ferreiro-Iglesias A, Waterboer T. et al. Absolute Risk of Oropharyngeal Cancer After an HPV16-E6 Serology Test and Potential Implications for Screening: Results From the Human Papillomavirus Cancer Cohort Consortium. J Clin Oncol 2022; 40 (31) 3613-3622
96 Busch CJ, Hoffmann AS, Viarisio D. et al. Detection of stage I HPV-driven oropharyngeal cancer in asymptomatic individuals in the Hamburg City Health Study using HPV16 E6 serology – A proof-of-concept study. EClinicalMedicine 2022; 53: 101659
97 Waterboer T, Brenner N, Klussmann JP. et al. Study results and related evidence do not support use of HPV16 L1 DRH1 antibodies as a cancer screening test. EBioMedicine 2020; 62: 103143
98 Rettig EM, Faden DL, Sandhu S. et al. Detection of circulating tumor human papillomavirus DNA before diagnosis of HPV-positive head and neck cancer. Int J Cancer 2022; 151 (07) 1081-1085
99 Schroeder L, Wichmann G, Willner M. et al. Antibodies against human papillomaviruses as diagnostic and prognostic biomarker in patients with neck squamous cell carcinoma from unknown primary tumor. Int J Cancer 2018; 142 (07) 1361-1368
100 Faden DL. Liquid biopsy for the diagnosis of HPV-associated head and neck cancer. Cancer Cytopathol 2022; 130 (01) 12-15
101 Reder H, Taferner VF, Wittekindt C. et al. Plasma Cell-Free Human Papillomavirus Oncogene E6 and E7 DNA Predicts Outcome in Oropharyngeal Squamous Cell Carcinoma. J Mol Diagn 2020; 22 (11) 1333-1343
102 Brenner N, Mentzer AJ, Hill M. et al. Characterization of human papillomavirus (HPV) 16 E6 seropositive individuals without HPV-associated malignancies after 10 years of follow-up in the UK Biobank. EBioMedicine 2020; 62: 103123
103 Dahlstrom KR, Anderson KS, Guo M. et al. Screening for HPV-related oropharyngeal, anal, and penile cancers in middle-aged men: Initial report from the HOUSTON clinical trial. Oral Oncol 2021; 120: 105397